Granted Patent
B2
US 12,729,239 · App. 18/043,715 · Granted Sep 8, 2026
Anti-CEACAM5 antibodies and conjugates and uses thereof
Inventors:
Jan Anderl (Darmstadt, DE); Sabine Raab-Westphal (Darmstadt, DE); Stefan Hecht (Darmstadt, DE); Carl Deutsch (Darmstadt, DE); Min Shan (Darmstadt, DE); Doreen Könning (Darmstadt, DE); Willem N. Sloot (Darmstadt, DE); Felix Hart (Darmstadt, DE); Christian Schröter (Darmstadt, DE); Lars Toleikis (Darmstadt, DE); Nir Berger (Yavne, IL)
Assignee:
MERCK PATENT GMBH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.
Claims (26)
1 . An immunoconjugate comprising an antibody covalently linked via a linker to exatecan, the immunoconjugate having a formula (IV):
wherein:
the antibody binds to human CEACAM5 protein and comprises:
a CDR1-H consisting of the amino acid sequence of SEQ ID NO: 3,
a CDR2-H consisting of the amino acid sequence of SEQ ID NO: 4,
a CDR3-H consisting of the amino acid sequence of SEQ ID NO: 5,
a CDR1-L consisting of the amino acid sequence of SEQ ID NO: 6,
a CDR2-L consisting of the amino acid sequence of SEQ ID NO: 7, and
a CDR3-L consisting of the amino acid sequence of SEQ ID NO: 8;
S is a sulfur atom of the antibody, and
n is between 1 and 10.
2 . The immunoconjugate according to claim 1 , wherein n is between 7 and 8.
3 . The immunoconjugate according to claim 1 , wherein n is between 7.5 and 8.0.
4 . A pharmaceutical composition, comprising; the immunoconjugate according to claim 1 , and a pharmaceutically acceptable carrier, diluent, and/or excipient.
5 . The immunoconjugate according to claim 1 , wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 10.
6 . The immunoconjugate according to claim 5 , wherein n is between 7 and 8.
7 . The immunoconjugate according to claim 5 , wherein n is between 7.5 and 8.0.
8 . A pharmaceutical composition, comprising: the immunoconjugate according to claim 5 , and a pharmaceutically acceptable carrier, diluent, and/or excipient.
9 . The immunoconjugate according to claim 1 , wherein the antibody comprises a heavy chain constant region (CH) comprising the amino acid sequence of SEQ ID NO: 11 and a light chain constant region (CL) comprising the amino acid sequence of SEQ ID NO: 12.
10 . The immunoconjugate according to claim 9 , wherein n is between 7 and 8.
11 . The immunoconjugate according to claim 9 , wherein n is between 7.5 and 8.0.
12 . A pharmaceutical composition, comprising; the immunoconjugate according to claim 9 , and a pharmaceutically acceptable carrier, diluent, and/or excipient.
13 . The immunoconjugate according to claim 1 , wherein the antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 13 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 14.
14 . The immunoconjugate according to claim 13 , wherein n is between 7 and 8.
15 . The immunoconjugate according to claim 13 , wherein n is between 7.5 and 8.0.
16 . A pharmaceutical composition, comprising; the immunoconjugate according to claim 13 , and a pharmaceutically acceptable carrier, diluent, and/or excipient.
Priority Claims (2)
EP 20194711
· Sep 4, 2020
· regional
EP 20195559
· Sep 10, 2020
· regional
Continuity (2)
Related Publication
20250122282A2
· Apr 17, 2025
References Cited (277)
US 5208020A
· Chari et al.
· 1993
[cited by applicant]
US 8287865B2
· Hansen
· 2012
[cited by examiner]
US 20150125386A1
· Hansen et al.
· 2015
[cited by applicant]
US 20170182179A1
· Ackler et al.
· 2017
[cited by applicant]
CA 3114137
· 2020
[cited by applicant]
EP 3101032
· 2016
[cited by applicant]
EP 3130608
· 2017
[cited by applicant]
KR 20180108183A
· 2018
[cited by applicant]
RU 2697522C1
· 2019
[cited by applicant]
WO 9608514
· 1996
[cited by applicant]
WO 0177342A1
· 2001
[cited by applicant]
WO 2004091668
· 2004
[cited by applicant]
WO 2007011968
· 2007
[cited by applicant]
WO 2008010101
· 2008
[cited by applicant]
WO 2009099741
· 2009
[cited by applicant]
WO 2011034660
· 2011
[cited by applicant]
WO 2014079886
· 2014
[cited by applicant]
WO 2014100762
· 2014
[cited by applicant]
WO 2015012904
· 2015
[cited by applicant]
WO 2015095755
· 2015
[cited by applicant]
WO 2015146132
· 2015
[cited by applicant]
WO 2015162291
· 2015
[cited by applicant]
WO 2015162293
· 2015
[cited by applicant]
WO 2015195904
· 2015
[cited by applicant]
WO 2015196089
· 2015
[cited by applicant]
WO 2015196167
· 2015
[cited by applicant]
WO 2016094517
· 2016
[cited by applicant]
WO 2016127081
· 2016
[cited by applicant]
WO 2016173682
· 2016
[cited by applicant]
WO 2016207089
· 2016
[cited by applicant]
WO 2016210108
· 2016
[cited by applicant]
WO 2017059158
· 2017
[cited by applicant]
WO 2017059160
· 2017
[cited by applicant]
WO 2017072662
· 2017
[cited by applicant]
WO 2017112624
· 2017
[cited by applicant]
WO 2017162663
· 2017
[cited by applicant]
WO 2017214456
· 2017
[cited by applicant]
WO 2018075842
· 2018
[cited by applicant]
WO 2018112253
· 2018
[cited by applicant]
WO 2018114798
· 2018
[cited by applicant]
WO 2018198091
· 2018
[cited by applicant]
WO 2019195665
· 2019
[cited by applicant]
WO 2019231879
· 2019
[cited by applicant]
WO 2019236954
· 2019
[cited by applicant]
WO 2020089811
· 2020
[cited by applicant]
WO 2020112588
· 2020
[cited by applicant]
WO 2020219287
· 2020
[cited by applicant]
Badri, et al., “Optimization of radiation dosing schedules for proneural glioblastoma”, J. Mathematical Biology, vol. 72, N. 5, 2016, 36 pages.
[cited by applicant]
Baylot et al., “TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression”, Results Probl Cell Differ, vol. 64, 2017, pp. 255-261.
[cited by applicant]
Mariuzza R.A., “The structural basis of antigen-antibody recognition”, Ann. Rev. Biophys, Biophys, Chem., vol. 16, 1987, pp. 139-159.
[cited by applicant]
Abe et al., “Targeted Sonodynamic Therapy of Cancer Using a Photosensitizer Conjugated with Antibody against Carcinoembryonic Antigen”, Anticancer Research, vol. 22, 2002, pp. 1575-1580.
[cited by applicant]
Abou-Alfa et al., “A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients with Biliary Tract Cancers”, American Journal of Clinical Oncology, vol. 28, No. 4, Aug. 2005, pp. 334…
[cited by applicant]
Abou-Alfa et al., “Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer”, Journal of Clinical Oncology, vol. 24, No. 27, Sep. 20, 2006, pp. 4441-…
[cited by applicant]
Ajani et al., “A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer”, Investigational New Drugs, vol. 23, 2005, pp. 479-484.
[cited by applicant]
Almagro et al., “Humanization of antibodies”, Frontiers in Bioscience, vol. 13, Jan. 1, 2008, pp. 1619-1633.
[cited by applicant]
Anselmi et al., “Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates”, Chemistry—A European Journal, vol. 27, 2021, pp. 1015-1022.
[cited by applicant]
Atsumi et al., “Urinary Metabolites of DX-8951, a Novel Camptothecin Analog, in Rats and Humans”. Arzneim.-Forsch./Drug Res. vol. 51 ,(I) 2001, pp. 253-257.
[cited by applicant]
Bajenova et al., “Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes”, Experimental Cell Research, vol. 324, 2014, pp. 115-123.
[cited by applicant]
Bajjuri et al., “The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity”, ChemMedChem, vol. 6, 2011, pp. 54-59.
[cited by applicant]
Bargh et al., “Cleavable linkers in antibody-drug conjugates”, Chemical Society Reviews, vol. 48, 2019, pp. 4361-4374.
[cited by applicant]
Beauchemin et al., “Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis”, Cancer Metastatsis Rev. vol. 32, 2013, pp. 643-671.
[cited by applicant]
Bechmann et al., “Heterogeneity of CEACAM5 in breast cancer”, Oncotarget, vol. 11, No. 43, 2020, pp. 3886-3899.
[cited by applicant]
Beck et al., “Strategies and challenges for the next generation of antibody-drug conjugates”, Nature Reviews, Drug Discovery, vol. 16, May 2017, pp. 315-337.
[cited by applicant]
Behr et al., “Cure of Metastatic Human Colonic Cancer in Mice with Radiolabeled Monoclonal Antibody Fragments”, Clinical Cancer Research, vol. 6, Dec. 2000, pp. 4900-4907.
[cited by applicant]
Behr et al., “Radioimmunotherapy of Small Volume Disease of Colorectal Cancer Metastatic to the Liver: Preclinical Evaluation in Comparison to Standard Chemotherapy and Initial Results of a Phase I Clinical Study”, Clin…
[cited by applicant]
Behr et al., “Radioimmunotherapy of Small-Volume Disease of Metastatic Colorectal Cancer”, American Cancer, vol. 94, No. 4, Feb. 15, 2002, pp. 1373-1381.
[cited by applicant]
Behr et al., “Therapeutic Efficacy and Dose-Limiting Toxicity of Auger-Electron vs. Beta Emitters in Radioimmunotherapy with Internalizing Antibodies: Evaluation of
[cited by applicant]
Birrer et al., “Antibody-Drug Conjugate-Based Therapeutics: State of the Science”, JNCI J Natl. Cancer Institute, vol. 111, No. 6, 2019, pp. 538-549.
[cited by applicant]
Blumenthal et al., “Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft”, Cancer Immunol Immunother, vol. 54, 2005, pp. 315-327.
[cited by applicant]
Blumenthal et al., “Comparison of Equitoxic Radioimmunotherapy and Chemotherapy in the Treatment of Human Colonic Cancer Xenografts”, Cancer Research, vol. 54, Jan. 1, 1994, pp. 142-151.
[cited by applicant]
Blumenthal et al., “Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)”, Cancer Research, vol. 65, No. 19, Oct. 1, 2005, pp. 8809-8817.
[cited by applicant]
Boige et al., “Phase I and Pharmacokinetic Study of the Camptothecin Analog DX-8951f Administered as a 30-Minute Infusion Every 3 Weeks in Patients with Advanced Cancer”, Journal of Clinical Oncology, vol. 18, No. 23, D…
[cited by applicant]
Boven et al., “New Analogues of Camptothecins Activity and Resistance”, Annals New York Academy of Sciences, 2000, pp. 175-177.
[cited by applicant]
Braybrooke et al., “Phase I and Pharmacokinetic Study of the Topoisomerase I Inhibitor, Exatecan Mesylate (DX-8951f), Using a Weekly 30-Minute Intravenous Infusion, in Patients with Advanced Solid Malignancies”, Annals …
[cited by applicant]
Braybrooke et al., “Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer”, Lung Cancer, vol. 41, 2003, pp. 215-219.
[cited by applicant]
Buchegger et al., “Radioimmunotherapy of Colorectal Cancer Liver Metastases: Combination with Radiotherapy”, Annals New York Academy of Sciences 2006, pp. 263-270.
[cited by applicant]
Burke et al. “Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates”, Molecular Cancer Therapeutics vol. 16, No. 1, Jan. 2017, pp. 116-123.
[cited by applicant]
Burke et al., “Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues”, Bioconjugate Chemistry 2009, vol. 20, No. 6, pp. 1242-1250.
[cited by applicant]
Chari et al., “Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy”, Angewandte Chemie International Edition, vol. 53, 2014, pp. 3796-3827.
[cited by applicant]
Chau et al., “Antibody—drug conjugates for cancer”, The Lancet, Aug. 31, 2019, vol. 394, pp. 793-804.
[cited by applicant]
Chen et al., “Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate”, World Journal of Gastroenterol, vol. 13, No. 43, Nov. 21, 2007, pp. 5765-5770.
[cited by applicant]
Chen et al., “Cloning, Isolation, and Characterization of Mammalian Legumain, an Asparaginyl Endopeptidase”, The Journal of Biological Chemistry, vol. 272, No. 12, Mar. 21, 1997, pp. 8090-8098.
[cited by applicant]
Chester et al., “Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer”, Cancer Chemother. Pharmacol., vol. 46, 2000, pp. S8-S12.
[cited by applicant]
Chuprakov et al., “Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Anti-Drug Conjugates”, Bioconjugate Chemistry, vol. 32, 2021, pp. 746-754.
[cited by applicant]
Clamp et al., “A Phase IIA Study of the Topoisomerase I Inhibitor, Exatecan Mesylate (DX-8951f), Administered at two different dose schedules in Patients with Platinum- and Taxane-Resistant/Refractory Ovarian Cancer”, G…
[cited by applicant]
Compain et al., “A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy”, European Journal of Medicinal Chemistry, vol. 158, 2018, pp. 1-6.
[cited by applicant]
Cortés et al., “Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer”, The New England Journal of Medicine, vol. 386, No. 12, Mar. 24, 2022, pp. 1143-1154.
[cited by applicant]
Criscitiello et al., “Antibody-drug conjugates in solid tumors: a look into novel targets”, Journal of Hematology & Oncology, vol. 14, No. 20, pp. 1-18.
[cited by applicant]
Dall et al., “Structure and function of legumain in health and disease”, Biochimie, vol. 122, 2016, pp. 126-150.
[cited by applicant]
David M. Goldenberg, “Carcinoembryonic Antigen as a Target Cancer Antigen for Radiolabeled Antibodies: Prospects for Cancer Imaging and Therapy”, Tumor Biol., vol. 16, 1995, pp. 62-73.
[cited by applicant]
Decary et al., “Abstract 1688: A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors”, Experimental and Molecular Therapeutics, Cancer Research, vol. 75, Issu…
[cited by applicant]
Decary et al., “Preclinical Activity of SAR408701: A Novel Anti-CEACAM5- maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors”, Clinical Cancer Research, vol. 26, No. 24, Dec. 15,…
[cited by applicant]
Delucia et al., “Regulation of CEACAM5 and Therapeutic Efficacy of an Anti- CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer”, Clinical Cancer Research, vol. 27, No. 3, Feb. 1, 2021, pp. 759-774.
[cited by applicant]
Doi et al., “Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a…
[cited by applicant]
Dong et al., “Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan”, European Journal of Medicinal Chemistry, vol. 167, 2019, pp. 583-593.
[cited by applicant]
Dotan et al., “Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer”, Journal of Clinical Oncology, vol. 35, No. 29…
[cited by applicant]
Drago et al. “Unlocking the potential of antibody-drug conjugates for cancer therapy”, Nature Reviews, Clinical Oncology, 2021, 18 pages.
[cited by applicant]
Dubowchik et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 1.A Model Study of Structural Requirements for Efficient Release of Doxorubicin”, Bioorganic & Medicinal Chemistry Letter, vol. 8, 1998, pp. 3341-3346.
[cited by applicant]
Ebrahimnejad et al., “Cell Adhesion Molecule CEACAM1 Associates with Paxillin in Granulocytes and Epithelial and Endothelial Cells”, Rapid Communication, Experimental Cell Research, vol. 260, 2000, pp. 365-373.
[cited by applicant]
Edupuganti et al., “Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment”, Recent Patents on Anti-Cancer Drugs Discovery, vol. 16, No. 4, 2021, pp. 479-497.
[cited by applicant]
Elie Dolgin, “Specter of eye toxicity looms over BCMA-targeted therapy”, Nature Biotechnology, vol. 38, Dec. 2020, pp. 1363-1370.
[cited by applicant]
Esteva et al., “A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for 5 Days Every 3 Weeks to Patients with Metastatic Breast Carcinoma”, Cancer, vol. 98, No. 5, Sep. 1, 2003, pp. 900-907.
[cited by applicant]
Ford et al., “Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer”, British Journal of Cancer, vol. 47, 1983, pp. 035-042.
[cited by applicant]
Francis et al., A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or the other CEA producing tumours, British Journal of Cancer, vol. 87, 2002, pp. 600-60…
[cited by applicant]
Fu et al., “DNA damaging agent-based antibody-drug conjugates for cancer therapy”, Antibody Therapeutics, vol. 1, No. 2, 2018, pp. 43-53.
[cited by applicant]
Garrison et al., “A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies”, Clinical Cancer Research, vol. 9, Jul. 2003, pp. 252…
[cited by applicant]
Gazzah et al., “Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation …
[cited by applicant]
Giles et al., “Phase I and Pharmacokinetic Study of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin, on a Daily-Times-Five Schedule in Patients with Advanced Leukemia” Clinical Cancer Research, vol. 8, Jul. 2002…
[cited by applicant]
De Goeij et al., “New developments for antibody-drug conjugate-based therapeutic approaches”, Current Opinion in Immunology, vol. 40, pp. 14-23.
[cited by applicant]
Gold et al., “Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques”, The Journal of Experimental Medicine, vol. 121, Nov. 16, 1964, 33 pages.
[cited by applicant]
De Gooyer et al., “Mutimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using In-Labeled SGM-101”, Clinical Cancer Research, vol. 26, No. 22 Nov. 15, 2020, pp. 5934-5942.
[cited by applicant]
De Gooyer et al., “Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin”, Nature Communications, vol. 13, No. 2621, 2022, pp. 1-10.
[cited by applicant]
Govindan et al., “Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug”, American Chemical Society, Molecular Pharmaceutics, vol. 12, 2015, pp. 18…
[cited by applicant]
Govindan et al., “CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates”, Clinical Cancer Research, vol. 15, No. 19, Oct. 1, 2009, pp. 6052-6061.
[cited by applicant]
Gregson et al., “Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers”, European Journal of Medicinal Chemistry, vol. 179, 2019, pp. 591-607.
[cited by applicant]
Haikala et al., “EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd”, Cancer Research, vol. 82, No. 1, Jan. 1, 2022, pp. 130-141.
[cited by applicant]
Hajjar et al., “Phase I Radioimmunotherapy Trial with Iodine-131-Labeled Humanized MN-14 Anti-Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer”, Clinical Co…
[cited by applicant]
Hamblett et al., “SLC46A3 is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm”, American Association for Cancer Research, vol. 75, No. 24, Dec. 15, 2015…
[cited by applicant]
Hamilton et al., 204TiP “A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)”, Annals of Oncology, vol. 33, Issue S3, 2022, p. S220.
[cited by applicant]
Hamilton et al., “Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation”, ChemMedChem, vol. 16, 2021, pp. 1077-1081.
[cited by applicant]
Han et al., “The old CEACAMs find their new role in tumor immunotherapy”, Investigational New Drug, vol. 38, 2020, pp. 1888-1898.
[cited by applicant]
Hansen et al., “Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen”, Cancer, vol. 71, No. 11, Jun. 1, 1993, pp. 3478-3485.
[cited by applicant]
Van Hattum et al., “Induction of Breast Cancer Resistance Protein by the Camptothecin Derivative DX-8951f Is Associated with Minor Reduction of Antitumour Activity”, British Journal of Cancer, vol. 87, 2002, pp. 665-672.
[cited by applicant]
Van Hattum et al., “The Activity Profile of the Hexacyclic Camptothecin Derivative DX-8951f in Experimental Human Colon Cancer and Ovarian Cancer”, Biochemical Pharmacology, vol. 64, 2002, pp. 1267-1277.
[cited by applicant]
Haugen et al., “High expression of the cysteine proteinase legumain in colorectal cancer Implications for therapeutic targeting”, European Journal of Cancer, vol. 51, 2015, pp. 9-17.
[cited by applicant]
He et al., “Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy”, American Chemical Society, NANO Letters, vol. 17, 2…
[cited by applicant]
Heather Donaghy, “Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates”, vol. 8, No. 4, 2016, pp. 659-671.
[cited by applicant]
Hezareh et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1”, Journal of Virology, vol. 75, No. 24, Dec. 2001, pp. 12161-12168.
[cited by applicant]
Hollandsworth et al., “A review of tumor-specific fluorescence-guided surgery for colorectal cancer”, Surgical Oncology, vol. 36, 2021, pp. 84-90.
[cited by applicant]
Hyunbo Shim, “Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations”, Biomolecules, vol. 10, No. 360, 2020, pp. 1-31.
[cited by applicant]
Imakiire et al., “Generation, Immunologic Characterization and Antitumor Effects of Human Monoclonal Antibodies for Carcinoembryonic Antigen”, Int. Journal of Cancer, vol. 108, 2004, pp. 564-570.
[cited by applicant]
Kazuhiro Inoue et al., “CM-Dextran-Polyalcohol-Camptothecin Conjugate”, Polymer Drugs in the Clinical Stage, edited by Maeda et al., 2003, pp. 145-153.
[cited by applicant]
International Search Report issued Nov. 16, 2021, in PCT/EP2021/072595, 8 pages.
[cited by applicant]
Mineko Ishii et al., “Growth Inhibitory Effect of a New Camptothecin Analog, DX-8951f, on Various Drug-Resistant Sublines Including BCRP-Mediated Camptothecin Derivative-Resistant Variants Derived from the Human Lung Ca…
[cited by applicant]
Junko Iwano et al., “Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies”, Drug Metabolism and …
[cited by applicant]
Tomomi Nakayama Iwata et al., “A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model”, Molecular Cancer Therapeutics, vol. 17, No. 7, Jul. 2018, pp. 14…
[cited by applicant]
De Jager et al., “DX-8951f: Summary of Phase I Clinical Trials”, Annals New York Academy of Sciences 922, 2000, pp. 260-273.
[cited by applicant]
Jänne et al., “Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer”, American Association of Cancer Research, Cancer Discovery, Jan. 2022, pp. 74-…
[cited by applicant]
Jänne et al., “P01.03 Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC”, Journal of Thoracic Oncology 2021, vo…
[cited by applicant]
Jeffrey et al., “Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates”, Bioconjugate Chemistry, vol. 17, 2006, pp. 831-840.
[cited by applicant]
Jeffrey et al., “Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents”, ACS Medicinal Chemistry Letters, American Chemical Society, vol. 1, 2010, pp. 277-280.
[cited by applicant]
Jeffrey et al., “Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker”, Bioorganic & Medicinal Chemistry Letter, vol. 17, 2007, pp. 2278-2280.
[cited by applicant]
Johnson et al., “A Vindesine-Anti-Cea Conjugate Cytotoxic for Human Cancer Cells In Vitro”, British Journal of Cancer, vol. 44, No. 372, 1981, pp. 472-475.
[cited by applicant]
Joto et al., “DX-8951f, a Water-Soluble Camptothecin Analog, Exhibits Potent Antitumor Activity against a Human Lung Cancer Cell Line and Its SN-38-Resistant Variant”, International Journal of Cancer, vol. 72, 1997, pp.…
[cited by applicant]
Kabraji et al., “Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases”, Clinical Cancer Research, vol. 29, No. 1, Jan. 1, 2023, pp. 174-182.
[cited by applicant]
Kammerer et al., “Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families”, BMC Biology, vol. 8, No. 12, 2010, pp. 1-21.
[cited by applicant]
Karol Michal Kacprzak, “Chemistry and Biology of Camptothecin and its Derivatives”, Springer-Verlag Berlin Heidelberg, 2013, pp. 643-682.
[cited by applicant]
Khongorzul et al., “Antibody-Drug Conjugates: A Comprehensive Review”, Molecular Cancer Research, vol. 18, No. 1, Jan. 2020, pp. 3-19.
[cited by applicant]
Kimio Yonesaka, “HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors”, Cancers, vol. 13, No. 1047, 2021, pp. 1-13.
[cited by applicant]
Koganemaru et al. “U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer”, Molecular Cancer Therapeutics, vol. 18, No. 11, 2019, pp. 2043-2050.
[cited by applicant]
Koyama et al., “Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression”, PL…
[cited by applicant]
Kumazawa et al., “DE-310, a Novel Macromolecular Carrier System for the Camptothecin Analog DX-8951f: Potent Antitumor Activities in Various Murine Tumor Models”, Cancer Science, vol. 95, No. 2, Feb. 2004, pp. 168-175.
[cited by applicant]
Kumazawa et al., “Potent and Broad Antitumor Effects of DX-8951f, a Water-Soluble Camptothecin Derivative, against Various Human Tumors Xenografted in Nude Mice”, Cancer Chemotherapy and Pharmacology, vol. 42, 1998, pp.…
[cited by applicant]
Lau et al., “Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins”, Molecular Pharmaceutics, American Chemical Society, Aug. 1, 2018, 10 pages.
[cited by applicant]
Lawrence et al., “Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explant adult and pediatric human tumor cells”, Anti-Cancer Drugs, vol. 10, 1999, pp. 655-661.
[cited by applicant]
L. Nathan Tumey, “Next Generation Payloads for ADCs”, M.Damelin, (ed.) Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham., 2018, pp. 187-214.
[cited by applicant]
Lee et al., “Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate”, Molecules, vol. 25, No. 151…
[cited by applicant]
Lerchen et al., “Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation”, Chemistry European Journal, vol. 25, 2019, pp. 8208-8213.
[cited by applicant]
Lerchen et al., “Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads” Bioconjugate Chemistry, 2020, vol. 31, pp. 1893-1898.
[cited by applicant]
Lewēn et al., “A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis”, Cancer Immunol Immunother., vol. 57, 2008, pp. 507-515.
[cited by applicant]
Na Li et al., “Effects of legumain as a potential prognostic factor on gastric cancers” Medical Oncology, vol. 30, No. 621, 2013, pp. 1-12.
[cited by applicant]
Bob T. Li et al., “Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer”, The New England Journal of Medicine, vol. 386, 2022, pp. 241-251.
[cited by applicant]
Fu Li et al., “Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models”, Cancer Research, vol. 76, No. 9, May 1, 2016, pp. 2710-2719.
[cited by applicant]
Yang Li et al., “Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanparticales for efficient anticancer drug delivery and in situ monitoring of drug release”, Nanoscale, vol. 12, 2020, pp. 2673-2685.
[cited by applicant]
Hongcheng Liu et al., “Disulfide bond structures of IgG molecules—Structural variations, chemical modifications and possible impacts to stability and biological function”, Landes Bioscience, vol. 4, No. 1, Jan./Feb. 201…
[cited by applicant]
Ze Liu et al., “Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment”, Nature Communications, vol. 5, Issue 4280, Jun. 27, 2014, pp. 1-11.
[cited by applicant]
Lyon et al., “Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index”, Nature Biotechnology, vol. 33, No. 7, Jul. 2015, pp. 733-736.
[cited by applicant]
Lyski et al., “Development of Novel Antibody-Camptothecin Conjugates”, Molecular Cancer Therapeutics, vol. 20, Issue 2, Feb. 2021, pp. 329-339.
[cited by applicant]
Manoury et al., “Asparagine Endopeptidase can Initiate the Removal of the MHC Class II Invariant Chain Chaperone” Immunity, Humana Press, vol. 18, Apr. 2003, pp. 489-498.
[cited by applicant]
Marc Damelin, “Innovations for Next-Generation Antibody-Drug Conjugates” Cancer Drug Discovery and Development 2018, Humana Press, Cham., 2018, 358 pages.
[cited by applicant]
Marcin Poreba et al., “Recent advances in the development of legumain-selective chemical probes and peptide prodrugs”, Biological Chemistry vol. 400, No. 12, 2019, pp. 1529-1550.
[cited by applicant]
Masters et al., “Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads”, Invest. New Drugs, 2018, vol. 36, pp. 121-135.
[cited by applicant]
Masubuchi et al., “A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the in Vitro Colony-Forming Unit Granulocyte/Macrophage Assay”, Clincal Cancer Research, vol. 10, Oct. 1, 2004, pp. 67…
[cited by applicant]
Mattock et al., “Legumain and cathepsin-L expression in human unstable carotid plaque” Atherosclerosis, vol. 208, 2010, pp. 83-89.
[cited by applicant]
Mauricio et al., “Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressi…
[cited by applicant]
Bodet-Milin et al., “Clinical Result in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches”, Frontiers in Medicine, vol. 6, Article 124, Jun. 2019, …
[cited by applicant]
Miller et al., “Enzyme-Agnostic Lysosomal Screen Indentifies New Legumain-Cleavable ADC Linkers”, Bioconjugate Chemistry, vol. 32, 2021, pp. 842-858.
[cited by applicant]
Minami et al., “Phase I and Pharmacological Study of a New Camptothecin Derivative, Exatecan Mesylate (DX-8951f), Infused over 30 Minutes Every Three Weeks” Clinical Cancer Research, vol. 7, Oct. 2001, pp. 3056-3064.
[cited by applicant]
Mitsui et al., “A New Water-Soluble Camptothecin Derivative, DX-8951f, Exhibits Potent Antitumor Activity against Human Tumors in Vitro and in Vivo” Japanese Journal of Cancer Research, vol. 86, Aug. 1995, pp. 776-782.
[cited by applicant]
Modi et al., “Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study”, Journal of Clinical Oncology, vol. 38, Issue 17, 2020, p…
[cited by applicant]
Modi et al., “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer”, The New England Journal of Medicine, vol. 387, No. 1, Jul. 7, 2022, pp. 9-20.
[cited by applicant]
Morita et al., “Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells”, FEBS Letters, vol. 581, 2007, pp. 1417-1424.
[cited by applicant]
Murakami et al., “A reference of the GOLD classification of monoclonal antibodies against carcinoembryonic antigen to the domain structure of the carcinoembryonic antigen molecule”, Hybridoma, vol. 14, No. 1, 1995, pp. …
[cited by applicant]
Nagai et al., “Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan(DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys”, Xenobiotica, vol. 49, No. 9, 2019, pp. 1086-109…
[cited by applicant]
Nakada Takashi et al., “Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads”, Bioorganic & Medicinal Chemistry Letters, vol. 26, 2016, pp. 1542-1545.
[cited by applicant]
Nakada et al., “The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy”, Chem. Pharm Bull, vol. 67, No. 3, 2019, pp. 173-185.
[cited by applicant]
Nielsen et al., “Carcino-Embryonic Antigen (Cea) In Gastric Adenocarcinomas”, Acta. Path. Microbiol. Immunil. Scand. Sect. A, vol. 90, 1982, pp. 393-396.
[cited by applicant]
Nomoto et al., “Characterization of a Human Small-Cell Lung Cancer Cell Line Resistant to a New Water-Soluble Camptothecin Derivative, DX-8951f”, Japanese Journal of Cancer Research, vol. 89, Nov. 1998, pp. 1179-1186.
[cited by applicant]
Ochi et al., “A Possible Mechanism for the Long-Lasting Antitumor Effect of the Macromolecular Conjugate DE-310: Mediation by Cellular Uptake and Drug Release of Its Active Camptothecin Analog DX-8951”, Cancer Chemother…
[cited by applicant]
Ogitani et al., “Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity”, Cancer Scienc…
[cited by applicant]
Ogitani et al., “DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1”, Clinical Cancer Research, vol. 22, No. 20, …
[cited by applicant]
Oguma et al., “High-Performance Liquid Chromatographic Analysis of Lactone and Hydroxy Acid of New Antitumor Drug, DX-8951 (Exatecan), in Mouse Plasma”,Biological & Pharmaceutical Bulletin, vol. 24, No. 2, 2001, pp. 176…
[cited by applicant]
Oguma et al., “Sensitive High-Performance Liquid Chromatographic Method for the Determination of the Lactone Form and the Lactone plus Hydroxy-Acid Forms of the New Camptothecin Derivative DX-8951 in Human Plasma Using …
[cited by applicant]
Oguma et al., “Validation Study of Assay Method for DX-8951 and Its Metabolite in Human Plasma and Urine by High-Performance Liquid Chromatography/Atmospheric Pressure Chemical Ionization Tandem Mass Spectrometry ”, Bio…
[cited by applicant]
Okajima et al., “Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells”, Molecular Cancer Therapeutics, vol. 20, No. 12,…
[cited by applicant]
P. Maxwell, “Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker” British Journal of Biomedical Science, vol. 56, 1999, pp. 209-214.
[cited by applicant]
Panousis et al., “Monoclonal Antibody-Directed Cytotoxic Therapy”, Drugs & Aging, vol. 15, No. 1, Jul. 1999, pp. 1-13.
[cited by applicant]
Peng et al., “The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA”, PLOS ONE, vol. 7, No. 5, e36412, May 2012, pp. 1-14.
[cited by applicant]
Poreba et al., “Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes”, Cell Chemical Biology, vol. 23, Aug. 18, 2016, pp. 1023-1035.
[cited by applicant]
Poreba et al., “Unnatural amino acids increase sensitivity and provide for the design of highly selective caspase substrates” Cell Death and Differentiation, vol. 21, 2014, pp. 1482-1492.
[cited by applicant]
Pouzin et al., “Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate”, Journal of Pharmacokinetics and Pharmacodynamics…
[cited by applicant]
Pouzin et al., “Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study”, CPT Pharmacometrics & Systems Pharmacology, vol. 11, 2022, pp. 384-394.
[cited by applicant]
Reichardt et al., “Exatecan in Pretreated Adult Patients with Advanced Soft Tissue Sarcoma: Results of a Phase II-Study of the EORTC Soft Tissue and Bone Sarcoma Group”, European Journal of Cancer, vol. 43, 2007, pp. 10…
[cited by applicant]
Rijpkema et al., “SPECT—and Fluorescence Image-Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen-Targeting Antibody”, Journal of Nuclear Medicine, vol. 55, No. 9, Sep. 2014, pp. 1519-1524.
[cited by applicant]
Riva et al., “Treatment of Metastatic Colorectal Cancer by Means of Specific Monoclonal Antibodies Conjugated with Iodine-131: a Phase II Study”, Nuclear Medicine and Biology, vol. 18, No. 1, 1991, pp. 109-119.
[cited by applicant]
Rivault et al., “A new linker for glucuronylated anticancer prodrugs”, Bioorganic & Medicinal Chemistry, vol. 12, No. 4, 2004, pp. 675-682.
[cited by applicant]
Paula Rivas Lopez et al., “β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate”, Organic & Biomolecular Chemistry, vol. 17, 2019, pp. 4705-4710.
[cited by applicant]
Rowinsky et al., “DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily—Times—Five Schedule: A Phase I and Pharmacokinetic Study in Patients with Advanced Solid Malignancies”, Journal of Clinical Oncology: Official Jou…
[cited by applicant]
Royce et al., “A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum”, Investigational New Drug…
[cited by applicant]
Royce et al., “Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog”, Journal of Clinical Oncology, vol. 19, No. 5 Mar. 1, 2001, pp. 1493-1500.
[cited by applicant]
Martinez-Sabadell et al., “The target antigen determines the mechanism of acquired resistance to T cell-based therapies”, Cell Reports, vol. 41, No. 111430, 2022, 22 pages.
[cited by applicant]
Sahlmann et al., “Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study”, Cancer, Feb. 15, 2017,…
[cited by applicant]
Schlothauer et al., “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions”, Protein Engineering, Design & Selection, vol. 29, No. 10, 2016, pp. 457-466.
[cited by applicant]
Schmidt et al., “Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability”, Cancer Immunol Immunother, vol. 57, 2008, pp. 1879-1890.
[cited by applicant]
Sharkey et al., “Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)”, Molecular Cancer Therapeutics, vol. 17, No. 1, Jan. 2018, pp. 196…
[cited by applicant]
Sharkey et al., “Clinical Evaluation of Tumor Targeting with a High-Affinity Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14”, Cancer, vol. 71, No. 6, Mar. 15, 1993, pp. 2082-2096.
[cited by applicant]
Sharkey et al., “Evaluation of a Complementarity-Determining Region-Grafted (Humanized) Anti-Carcinoembryonic Antigen Monoclonal Antibody in Preclinical and Clinical Studies”, Cancer Research (Suppl.), vol. 55, Dec. 1, …
[cited by applicant]
Sharkey et al., “Murine Monoclonal Antibodies against Carcinoembryonic Antigen: Immunological, Pharmacokinetic, and Targeting Properties in Humans”, Cancer Research, vol. 50, May 1, 1990, pp. 2823-2831.
[cited by applicant]
Sharkey et al., “Radioimmunotherapy of Human Colonic Cancer Xenografts with
[cited by applicant]
Sharma et al., “Phase I Study of Topoisomerase I Inhibitor Exatecan Mesylate (DX-8951f) given as Weekly 24-Hour Infusions Three of Every Four Weeks”, Clinical Cancer Research, vol. 7, Dec. 2001, pp. 3963-3970.
[cited by applicant]
Shastry et al., “Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer”, The Breast, vol. 66, 2022, pp. 169-177.
[cited by applicant]
Shi et al., “Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer”, BMC Cancer, vol. 22, No. 1291, 2022, pp. 1-14.
[cited by applicant]
Shinmi et al., “Novel anticarcinoembryonic antigen-drug conjugates has antitumor activity in the existence of soluble antigen” Cancer Medicine, vol. 6, No. 4, 2017, pp. 798-808.
[cited by applicant]
Shiose et al., “Quantitative Acid Hydrolysis of DE-310, a Macromolecular Carrier System for the Camptothecin Analog DX-8951f”. Journal of Pharmaceutical and Biomedical Analysis, vol. 43, 2007, pp. 1290-1296.
[cited by applicant]
Shiose et al., “Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors” Biological and Pharmaceutical Bulletin, vol. 30, No. 12, 2007, pp. 2365-2370.
[cited by applicant]
Shirahama-Noda et al., “Biosynthetic Processing of Cathepsins and Lysosomal Degradation Are Abolished in Asparaginyl Endopeptidase-deficient Mice” Journal of Biological Chemistry, vol. 278, No. 35, Aug. 29, 2003, pp. 33…
[cited by applicant]
Shitara et al., “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer”, The New England Journal Medicine, vol. 382, No. 25, Jun. 18, 2020, pp. 2419-2430.
[cited by applicant]
Shitara et al., “Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study”, Lancet Oncology, vol. 20, Jun. 2019, pp. 827-836.
[cited by applicant]
Siena et al., “Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial”, Lancet Oncology, vol. 22, 2021, pp. 779-789.
[cited by applicant]
Soepenberg et al., “Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors”, Clinical Cancer Research, vol. 11, Jan. 15, 2005, pp. 703-711.
[cited by applicant]
Starling, et al., “In Vivo Antitumor Activity of a Panel of Four Monoclonal Antibody-Vinca Alkaloid Immunoconjugates Which Bing to Three Distinct Epitopes of Carcinoembryonic Antigen”, Bioconjugate Chemistry, vol. 3, 19…
[cited by applicant]
Stein et al., “A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy”, Molecular Cancer Ther…
[cited by applicant]
Stern et al., “A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain”, Bioconjugate Chem., vol. 20, 2009, pp. 500-510.
[cited by applicant]
Steuer et al., “Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations”, Lung Cancer—Non-Small Cell Metastatic, Journal of Cli…
[cited by applicant]
Strickland et al., “Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma”, Journal of Pathology, vol. 218, 2009, pp. 380-390.
[cited by applicant]
Sun et al., “Efficacy of Camptothecin Analog DX-8951f (Exatecan Mesylate) on Human Pancreatic Cancer in an Orthotopic Metastatic Model”, Cancer Research, vol. 63, Jan. 1, 2003, pp. 80-85.
[cited by applicant]
Takegawa et al., “[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification”, International Journal of Cancer, vol. 145, 2019, pp. 3414-3424.
[cited by applicant]
Takegawa et al., “DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance”, International Journal of Cancer, vo…
[cited by applicant]
Takiguchi et al., “Antitumor Effect of DX-8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT-11-Resistant Variants Cultured in Vitro and Xenografted into Nude Mice”, Japanese Journal of Can…
[cited by applicant]
Tamura et al., “Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study”, Lancet Oncology, vol. 20, Jun. 201…
[cited by applicant]
Thomas et al., “Targeting Topoisomerase I in the Era of Precision Medicine”, published online Jun. 21, 2019, Clinical Cancer Research, 26 pages.
[cited by applicant]
Tranoy-Opalinski et al., “β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update”, European Journal of Medicinal Chemistry, vol. 74, 2014, pp. 302-313.
[cited by applicant]
Tsai et al., “Growth Suppression of Human Colorectal Carcinoma in Nude Mice by Monoclonal Antibody C27-Abrin A Chain Conjugate” Dis Colon Rectum, vol. 38, No. 10, Oct. 1995, pp. 1067-1074.
[cited by applicant]
Tsuchikama et al., “Antibody-drug conjugates: recent advances in conjugation and linker chemistries”, Protein Cell, vol. 9, No. 1, 2018, pp. 33-46.
[cited by applicant]
Tsurutani et al., “Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors”, Cancer Discovery, May 2020, pp. 688-701.
[cited by applicant]
Turner et al., “The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review”, Biomolecules, vol. 11, No. 1819, 2021, pp. 1-16.
[cited by applicant]
Uppal et al., “Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)”, Clinical Cancer Research, vol. 21, No. 1, Jan. 1, 2015, pp. 123-133.
[cited by applicant]
Ichiro Uyama et al., “Improvement of Therapeutic Effect by Using Fab Fragment in the Treatment of Carcinoembryonic Antigen-positive Human Solid Tumors with Adriamycin-entrapped Immunoliposomes”, Japan Journal of Cancer …
[cited by applicant]
Verschraegen et al., “A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for 5 Days Every 3 Weeks to Patients with Advanced Ovarian, Tubal or Peritoneal Cancer Resistant to Platinum, Taxane …
[cited by applicant]
Verschraegen et al., “Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan”, Annals New York Academy of Sciences, 2000, pp. …
[cited by applicant]
Vey et al., “The Topoisomerase I Inhibitor DX-8951f Is Active in a Severe Combined Immunodeficient Mouse Model of Human Acute Myelogenous Leukemia”, Clinical Cancer Research, vol. 6, Feb. 2000, pp. 731-736.
[cited by applicant]
Viricel et al., “Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates”, Chemical Science, vol. 10, 2019, pp. 4048-4053.
[cited by applicant]
Wang et al., “CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial-mesenchymal transition via inhibiting MDM2”, Clinical Science, vol. 136, 2022, pp. 1691-1710.
[cited by applicant]
Webley et al., “Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material”, British Journal of Cancer, vol. 84, No. 12, 2001, pp. 167…
[cited by applicant]
Wente et al., “DE-310, a Macromolecular Prodrug of the Topoisomerase-I-Inhibitor Exatecan (DX-8951), in Patients with Operable Solid Tumors” Investigational New Drugs, vol. 23, 2005, pp. 339-347.
[cited by applicant]
Written Opinion issued Nov. 16, 2021, in PCT/EP2021/072595, 7 pages.
[cited by applicant]
Yamaguchi et al., “Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment—Native Patients With Human Epidermal Growth Factor Receptor 2—Low Gastric or Gastroesophageal Junction Adenocarcinoma:…
[cited by applicant]
Yazaki et al., “Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated Fragments”, Bioconjugte Chemistry, vol. 12, 2001, pp. 220-228.
[cited by applicant]
Zalcberg et al., “A Phase I/II Study of the Intralesional Injection of Ricin-Monoclonal Antibody Conjugates in Patients with Hepatic Metastases”, European Journal of Cancer, vol. 30A, No. 9, 1994, pp. 1227-1231.
[cited by applicant]
Linshu Zhao et al., “An enzyme-linked immunosorbent assay for human carcinoembryonic antigen-related cell adhesion molecule 8, a biological marker of granulocyte activities in vivo”, Journal of Immunological Methods, vo…
[cited by applicant]
Hui Zhao et al., “A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise”, Molecular Cancer Therapeutics, vol. 16, No. 9, Sep. 2017, pp. 1866-1876.
[cited by applicant]
Zheng et al., “A Novel Anti-CEACAM5 Monoclonal Antibody, CC4, Suppresses Colorectal Tumor Growth and Enhances NK Cells-Mediated Tumor Immunity”, PLOS ONE, vol. 6, No. 6, Jun. 2011, e21146, pp. 1-11.
[cited by applicant]
Singer, M. et al., Genes and Genomes, Moscow, Mir (1998), vol. 1, pp. 63-64 (w/ English translation) 6 pgs.
[cited by applicant]
Roit, A. et al., Immunology (2000), Moscow, ‘Mir’, pp. 110-111 (w/ English translation) 8 pgs.
[cited by applicant]
Edwards, B. M. et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Singler Protein, BLyS”, JMB (2003), vol. 334, pp. 103-118.
[cited by applicant]
Lloyd, C. et al., “Modelling the Human Immune Response: Performance of the 10 Human Antibody Repertoire against a Broad Panel of Therapeutically Relevant Antigens”, Protein Engineering, Design & Selection (2009), vol. 2…
[cited by applicant]
Office Action dated Jul. 17, 2026 issued in related Russian Application No. 2023107684 (w/ English translation) 22 pgs.
[cited by applicant]